tradingkey.logo
tradingkey.logo
Search

Taysha Gene Therapies Inc

TSHA
Add to Watchlist
5.860USD
-0.015-0.26%
Close 07-31 16:00ETQuotes delayed by 15 min
1.87BMarket Cap
LossP/E TTM

TSHA Financials

See Taysha Gene Therapies Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Taysha Gene Therapies Inc Earnings Date

Latest Release
May 6, 2026
EPS / Forecast
-0.12/-0.10
Revenue / Forecast
0.00/680.00K
Period
FY2025 Earnings
Revenue(YoY)
9.77M
17.28%
EPS(YoY)
-0.34
4.50%
Analyst Rating
BUY
2026/08/02
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
Financial Indicators
EPS
-44.70%-0.12
-11.36%-0.08
2.78%-0.09
-0.36%-0.09
23.17%-0.08
-130.87%-0.07
89.77%-0.10
76.52%-0.09
62.65%-0.10
123.00%0.23
---0.93
---0.38
---0.28
---0.99
---2.79
----
----
----
----
----
Revenue
-100.00%0.00
171.27%5.49M
-100.00%0.00
78.60%1.99M
-32.51%2.30M
-43.90%2.02M
-62.33%1.79M
-53.57%1.11M
-27.52%3.41M
44.04%3.60M
--4.75M
--2.40M
--4.71M
--2.50M
--0.00
--0.00
--0.00
----
----
----
Net Profit
-96.99%-42.41M
-48.26%-27.85M
-28.24%-32.73M
-28.45%-26.88M
10.52%-21.53M
-139.35%-18.79M
78.20%-25.52M
14.92%-20.93M
-36.54%-24.06M
185.68%47.74M
-341.39%-117.09M
27.85%-24.60M
64.98%-17.62M
-10.59%-55.72M
48.18%-26.53M
16.70%-34.09M
-57.12%-50.32M
-175.06%-50.39M
-240.29%-51.19M
---40.93M
Net Margin
----
45.34%-507.77%
----
28.08%-1353.58%
-32.58%-935.23%
-170.13%-929.03%
42.14%-1427.52%
-83.24%-1882.01%
-88.38%-705.39%
159.48%1324.67%
---2467.07%
---1027.06%
---374.46%
---2227.14%
----
----
----
----
----
----
Gross Margin
----
0.00%100.00%
----
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
--100.00%
--100.00%
--100.00%
--100.00%
----
----
----
----
----
----
Debt to assets ratio
-47.07%16.39%
-46.81%14.70%
-32.59%16.22%
-34.49%12.49%
15.94%30.97%
16.86%27.65%
21.08%24.06%
-59.82%19.07%
-29.48%26.72%
-21.32%23.66%
--19.87%
--47.45%
--37.88%
--30.07%
--33.89%
----
----
----
----
----
Revenue
-100.00%0.00
171.27%5.49M
-100.00%0.00
78.60%1.99M
-32.51%2.30M
-43.90%2.02M
-62.33%1.79M
-53.57%1.11M
-27.52%3.41M
44.04%3.60M
--4.75M
--2.40M
--4.71M
--2.50M
--0.00
--0.00
--0.00
----
----
----
Operating profit
-103.01%-43.49M
-41.98%-28.30M
-61.56%-34.02M
-25.61%-26.75M
11.96%-21.42M
-26.18%-19.93M
-34.71%-21.06M
8.92%-21.30M
-46.93%-24.33M
15.52%-15.80M
38.59%-15.63M
29.93%-23.38M
66.65%-16.56M
62.39%-18.70M
49.77%-25.46M
18.15%-33.37M
-54.72%-49.65M
-170.72%-49.72M
-236.95%-50.68M
---40.77M
Net Profit
-96.99%-42.41M
-48.26%-27.85M
-28.24%-32.73M
-28.45%-26.88M
10.52%-21.53M
-139.35%-18.79M
78.20%-25.52M
14.92%-20.93M
-36.54%-24.06M
185.68%47.74M
-341.39%-117.09M
27.85%-24.60M
64.98%-17.62M
-10.59%-55.72M
48.18%-26.53M
16.70%-34.09M
-57.12%-50.32M
-175.06%-50.39M
-240.29%-51.19M
---40.93M
Current assets
133.83%282.25M
128.42%324.65M
85.66%299.95M
77.21%316.26M
-7.57%120.71M
-5.16%142.13M
-5.97%161.56M
229.80%178.47M
80.49%130.60M
55.44%149.87M
299.53%171.81M
-29.57%54.12M
-32.31%72.36M
-39.59%96.42M
-78.19%43.00M
-62.94%76.83M
-55.39%106.89M
-38.11%159.60M
-29.39%197.17M
1734.69%207.30M
Total current liabilities
-10.90%20.10M
1.24%26.55M
-2.40%28.63M
-25.83%25.35M
-41.62%22.56M
-28.65%26.23M
-83.74%29.34M
-32.51%34.18M
-29.05%38.64M
-41.46%36.76M
444.53%180.45M
17.90%50.64M
12.01%54.45M
21.34%62.79M
-23.31%33.14M
51.29%42.95M
156.45%48.62M
625.85%51.75M
271.77%43.21M
41.32%28.39M
Total assets
117.08%300.35M
114.09%343.32M
75.65%316.55M
66.34%333.33M
-9.57%138.36M
-7.16%160.36M
-7.94%180.22M
145.75%200.39M
50.59%153.00M
36.79%172.73M
75.63%195.77M
-42.71%81.54M
-38.79%101.60M
-40.98%126.28M
-53.76%111.47M
-41.15%142.33M
-31.65%165.98M
-17.35%213.96M
-13.69%241.04M
2036.95%241.86M
Total liabilities
6.13%88.41M
8.49%96.38M
6.72%97.56M
-7.56%84.60M
-15.98%83.30M
-9.16%88.84M
-62.67%91.42M
-22.87%91.53M
-14.93%99.15M
-21.97%97.79M
144.05%244.88M
8.24%118.66M
1.13%116.55M
5.70%125.33M
-0.30%100.34M
98.00%109.62M
477.50%115.25M
1464.49%118.57M
765.86%100.65M
175.58%55.37M
Total equity
284.94%211.94M
245.25%246.94M
146.62%218.99M
128.47%248.73M
2.25%55.06M
-4.55%71.53M
280.80%88.80M
393.33%108.87M
460.24%53.85M
7796.42%74.94M
-541.43%-49.11M
-213.46%-37.11M
-129.47%-14.95M
-99.01%949.00K
-92.08%11.13M
-82.46%32.71M
-77.24%50.73M
-62.04%95.38M
-47.54%140.39M
2225.94%186.50M
Net operating income
-85.64%-40.88M
-45.96%-26.72M
-11.80%-24.17M
6.15%-20.18M
-11.22%-22.02M
-13.59%-18.31M
-20.42%-21.61M
-14.58%-21.50M
1.92%-19.80M
-212.89%-16.12M
37.70%-17.95M
43.73%-18.77M
50.69%-20.18M
135.46%14.28M
9.78%-28.81M
-46.18%-33.35M
-85.79%-40.94M
-102.83%-40.26M
-375.48%-31.93M
---22.82M
Net investment
-715.09%-3.02M
-2000.00%-247.00K
-37.14%-48.00K
130.85%62.00K
-165.00%-371.00K
230.00%13.00K
99.00%-35.00K
-518.75%-201.00K
96.41%-140.00K
99.58%-10.00K
-15.56%-3.49M
100.59%48.00K
65.87%-3.90M
72.18%-2.37M
24.54%-3.02M
4.53%-8.11M
-2039.89%-11.43M
-40.80%-8.52M
-12809.68%-4.00M
---8.50M
Net financing
1467.31%711.00K
13981.23%49.56M
33.39%8.80M
206.93%216.29M
-136.36%-52.00K
91.60%-357.00K
-95.31%6.59M
18591.78%70.47M
94.05%-22.00K
-110.20%-4.25M
136637.86%140.63M
-96.60%377.00K
-245.79%-370.00K
357.63%41.67M
-100.34%-103.00K
--11.07M
---107.00K
714.37%9.11M
-89.07%29.98M
--0.00

FAQs

What is the total revenue of Taysha Gene Therapies Inc?

According to Taysha Gene Therapies Inc's FY2025 earnings report, its total revenue reached 9.77M, with a year-on-year change of 8.33M.

What are the current assets of Taysha Gene Therapies Inc?

According to Taysha Gene Therapies Inc's FY2025 earnings report, its current assets were 324.65M, with a year-on-year change of 128.42.

What are the total assets of Taysha Gene Therapies Inc?

According to Taysha Gene Therapies Inc's FY2025 earnings report, its total assets of Taysha Gene Therapies Inc were 343.32M, with a year-on-year change of 114.09.

What are the total liabilities of Taysha Gene Therapies Inc?

According to Taysha Gene Therapies Inc's FY2025 earnings report, its total liabilities of Taysha Gene Therapies Inc were 96.38M, with a year-on-year change of 8.49.

What is the total equity of Taysha Gene Therapies Inc?

According to Taysha Gene Therapies Inc's FY2025 earnings report, its total equity of Taysha Gene Therapies Inc was 246.94M, with a year-on-year change of 245.25.

What is the net operating income of Taysha Gene Therapies Inc?

According to Taysha Gene Therapies Inc's FY2025 earnings report, its net operating income of Taysha Gene Therapies Inc was -110.50M, with a year-on-year change of -27.56.

What is the net investment of Taysha Gene Therapies Inc?

According to Taysha Gene Therapies Inc's FY2025 earnings report, its net investment of Taysha Gene Therapies Inc was -604.00K, with a year-on-year change of -66.39.

What is the net financing of Taysha Gene Therapies Inc?

According to Taysha Gene Therapies Inc's FY2025 earnings report, its net financing of Taysha Gene Therapies Inc was 274.59M, with a year-on-year change of 258.08.

What is the Earnings Per Share (EPS) of Taysha Gene Therapies Inc?

According to Taysha Gene Therapies Inc's FY2025 earnings report, its Earnings Per Share (EPS) was -0.34, with a year-on-year change of 4.50.

What is the net income of Taysha Gene Therapies Inc?

According to Taysha Gene Therapies Inc's FY2025 earnings report, its net income was -109.00M, with a year-on-year change of -22.06.

What is the net margin of Taysha Gene Therapies Inc?

According to Taysha Gene Therapies Inc's FY2025 earnings report, its net profit margin was -1115.27, with a year-on-year change of -4.07.

What is the debt-to-asset ratio of Taysha Gene Therapies Inc?

According to Taysha Gene Therapies Inc's FY2025 earnings report, its debt-to-asset ratio was 14.70, with a year-on-year change of -47.26.

What is the Return on Equity (ROE) of Taysha Gene Therapies Inc?

According to Taysha Gene Therapies Inc's FY2025 earnings report, its Return on Equity (ROE) was -68.45, with a year-on-year change of 43.87.

What is the Return on Assets (ROA) of Taysha Gene Therapies Inc?

According to Taysha Gene Therapies Inc's FY2025 earnings report, its Return on Assets (ROA) was -43.28, with a year-on-year change of 19.28.

What is the operating profit of Taysha Gene Therapies Inc?

According to Taysha Gene Therapies Inc's FY2025 earnings report, its operating profit was -110.50M, with a year-on-year change of -27.56.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.